Biothera

Celniker and Schor join Eleven Biotherapeutics

Friday, September 23, 2011 11:09 AM

Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing protein-based therapeutics, has named Abbie Celniker, Ph.D., chief executive officer.

More... »

NWBT expands clinical sites in ongoing brain cancer trial

Thursday, August 4, 2011 11:36 AM

Northwest Biotherapeutics has expanded its number of clinical trial sites, and now has 12 sites across the U.S. open and active, where patients can enroll in the ongoing clinical trial of DCVax immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The company also reported that a substantial number of additional sites are in progress. With the 12 sites already open and active, and others in progress, the company is on track to fulfill its prior projection that it will have 15 sites open and active in Q3 of this year.

More... »

Northwest Biotherapeutics receives $4.55 million investment

Friday, July 8, 2011 12:54 PM

Northwest Biotherapeutics has announced a $4.55 million equity investment by The Richard M. Schulze Family Foundation.  The sale of newly issued common stock of the company to the foundation follows the investment of $3 million by investment funds managed by Whitebox Advisors. The foundation has been focused for a number of years on game-changing medical research and treatment breakthroughs.  

More... »

Northwest Biotherapeutics change, expands management team

Friday, June 10, 2011 11:28 AM

Northwest Biotherapeutics (NWBT), a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments and without toxicities, has added several executives to its management team.

More... »

Aires Pharmaceuticals appoints Edwin L. Parsley as CMO

Wednesday, May 4, 2011 01:05 PM

Aires Pharmaceuticals has hired Ed Parsley, D.O., as chief medical officer.  Parsley will be responsible for all clinical development activities for Aironite, the company's lead product for treatment of pulmonary arterial hypertension (PAH).

More... »

Talecris Biotherapeutics receives EU orphan drug designation for Plasmin

Friday, March 11, 2011 11:56 AM

Talecris Biotherapeutics has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot. 

More... »